SCHEDULE: Pfizer Amends NEXTCURE Stake, Holds 3.0% Passive Interest

Pfizer Inc. and its affiliate, Pfizer Ventures (US) LLC, filed an amended Schedule 13G, disclosing a combined beneficial ownership of 3.0% in NEXTCURE, INC. common stock as of December 31, 2025.

Summary

• Pfizer Inc. and Pfizer Ventures (US) LLC, a controlled affiliate, filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in NEXTCURE, INC.
• As of December 31, 2025, Pfizer Inc. beneficially owns 157,646 shares of NEXTCURE, INC. common stock, representing 3.0% of the class.
• Pfizer Ventures (US) LLC beneficially owns 131,109 shares, representing 2.5% of the class.
• The percentage of class outstanding is based on a total of 5,203,290 shares of common stock, which includes 1,815,049 shares issuable upon the exercise of pre-funded warrants.
• Pfizer Inc. holds sole voting and dispositive power over 26,537 shares and shared voting and dispositive power over 131,109 shares.
• Pfizer Ventures (US) LLC holds shared voting and dispositive power over 131,109 shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of NEXTCURE, INC.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as slightly positive due to the continued, albeit passive, investment by a major pharmaceutical entity like Pfizer in NEXTCURE, INC., which can be interpreted as a vote of confidence.

Positives

• Pfizer Inc., a major pharmaceutical company, maintains a beneficial ownership stake in NEXTCURE, INC., which could be interpreted as a signal of confidence in the company's long-term prospects.

Risks

• The filing itself does not detail specific risks related to NEXTCURE, INC.'s operations or financial health.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding NEXTCURE, INC.'s future performance or strategic direction.

Industry Context

StockSavvy.ai notes that strategic investments by large pharmaceutical companies like Pfizer into smaller biotech firms such as NEXTCURE, INC. are common, often indicating early-stage interest in potential pipeline assets or technologies. While this 13G filing is a routine disclosure of ownership below the control threshold, Pfizer's continued presence on the shareholder list can be viewed as a positive, albeit minor, endorsement within the competitive biotechnology sector.

Comparison to Industry Standards

• This filing is a standard Schedule 13G amendment, a routine disclosure for passive investors holding less than 20% of a company's stock. It aligns with regulatory requirements for transparency in beneficial ownership.
• The disclosed ownership percentages are typical for passive institutional investments and do not suggest an intent to influence control, which would necessitate a Schedule 13D filing.

Stakeholder Impact

• Shareholders of NEXTCURE, INC. may view Pfizer's continued, passive investment as a positive signal, potentially enhancing investor confidence.
• The filing does not indicate any direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

NEXTCURE, Pfizer, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Pharmaceutical Investment